ANEW HEALTH (HKEX Filing): "Functional Regeneration" pain management provider files for listing
NewTimeSpace News: On 31 August 2026, Anew Health Limited filed its listing application with the Hong Kong Stock Exchange, with VBG Capital Limited acting as the sole sponsor. The Company is a Hong Kong-based provider of pain management and functional enhancement services operating under the brand "Functional Regeneration" (機能再生). Its principal business is to provide a range of non-surgical, non-invasive and non-pharmaceutical pain management therapies to clients, and it also sells non-prescription topical products and dietary supplements.
The Company's services are delivered through three service centres located in Causeway Bay, Tsim Sha Tsui and Sha Tin in Hong Kong, each with a floor area of approximately 18,000 square feet. Its therapies are based on the "RDS+" methodology, inspired by the concept of meridian systems in traditional Chinese medicine, and utilise approximately 300 imported energy therapy devices sourced from Germany, South Korea and Japan. The services are provided by Chinese medicine practitioners, trained physiotherapists, senior functional enhancement consultants and nutritionists.
The Group's target clients are mainly middle-to-high-income individuals, who typically purchase prepaid packages. The average annual spending per client at the Company's service centres was approximately HKD 49,000, HKD 50,500 and HKD 60,000 in FY2024, FY2025 and FY2026 respectively. During the track record period, revenue from any single client did not account for 10% or more of the Group's total revenue, and the top five clients were all independent third parties.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CHINARES PHARMA (03320.HK): Unit completes 2026 bond issue at 1.48%
- CHINARES PHARMA (03320.HK): Pre-bid process starts on unit share issue
- CHI MER LAND (00978.HK): Acquires remaining 50% of Foshan Yiyun
- ESTUN (02715.HK): Zhu Zhangxing named CFO as Wu Kan steps down
- INNOSCIENCE (02577.HK): Trustee buys 2.25m more H shares